Biological evaluation of biopsies from adult cerebral astrocytomas: Cell-growth/cell-suicide ratios and their relationship to patient survival

Journal of Neuropathology and Experimental Neurology

Volumn 57, Issue 8, 1998, Pages 746-757

  Rhodes, Roy H ^a  

^a Northside Medical Center   (United States)

Author keywords

Apoptosis; Brain neoplasms; Cellular proliferation; Image analysis; Survival analysis

Indexed keywords

ADULT; AGED; APOPTOSIS; ARTICLE; ASTROCYTOMA; BRAIN BIOPSY; BRAIN TUMOR; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL ARTICLE; DNA STRAND BREAKAGE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR GROWTH;

EID: 0031851768     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199808000-00004     Document Type: Article

References (92)

1. Burger PC, Scheithauer BW, Vogel FS. Surgical pathology of the central nervous system and its coverings, 3rd ed. New York: Churchill Livingstone, 1991:193-234
2. Dinapoli RP, Brown LD, Arusell RM, et al. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma. J Clin Oncol 1993;11:1316-21
3. Ganju V, Jenkins RB, O'Fallon JR, et al. Prognostic factors in gliomas: A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer 1994;74: 920-27
4. Nitta T, Sato K. Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer 1995;75:2727-31
5. Sneed PK, Prados MD, McDermott MW, et al. Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery 1995;36:898-904
6. McKeever PE, Ross DA, Strawderman MS, Brunberg JA, Greenberg HS, Junck L. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol 1997;56:798-805
7. Russell DS, Rubinstein LJ. Pathology of tumours of the nervous system, 5th ed. Baltimore: Williams & Wilkins, 1989:83-350
8. Hutton JL, Smith DF, Chadwick DW. Prospective evaluation of a prognostic index for intrinsic supratentorial tumours. J Neurol Neurosurg Psychiatry 1995;59:92-94
9. Blankenberg FG, Teplitz RL, Ellia W, et al. The influence of volumetric tumor doubling time, DNA ploidy, and histologic grade on the survival of patients with intracranial astrocytomas. Am J Neuroradiol 1995;16:1001-12
10. Haapasalo HK, Sallinen PK, Helén PT, Rantala IS, Helin HJ, Isola JJ. Comparison of three quantitation methods for PCNA immunostaining: Applicability and relation to survival in 83 astrocytic neoplasms. J Pathol 1993;171:207-14
11. Theunissen PHMH, Blaauw G. Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytoma. Histopathology 1993;23:75-79
12. Ang LC, Plewes M, Tan L, Begley H, Agranovich A, Shul D. Proliferating cell nuclear antigen expression in the survival of astrocytoma patients. Can J Neurol Sci 1994;21:306-10
13. Korkolopoulou P, Christodoulou P, Lekka-Katsouli I, et al. Prognostic significance of proliferating cell nuclear antigen (PCNA) expression in gliomas. Histopathology 1994;25:349-55
14. Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 1994;34:674-78
15. Sallinen PK, Haapasalo HK, Visakorpi T, et al. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 1994;174:275-82
16. Wakimoto H, Aoyagi M, Nakayama T, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 1996;77: 373-80
17. Kirkegaard LJ, DeRose PB, Yao B, Cohen C. Image cytometric measurement of nuclear proliferation markers (MIB-1, PCNA) in astrocytomas: Prognostic significance. Am J Clin Pathol 1998;109: 69-74
18. Patsouris E, Davaki P, Kapranos N, Davaris P, Papageorgiou K. A study of apoptosis in brain tumors by in situ end-labeling method. Clin Neuropathol 1996;15:337-41
19. Quigley MR, Maroon JC. The relationship between survival and the extent of the resection in patients with supratentorial malignant gliomas. Neurosurgery 1991;29:385-88
20. Ellison DW, Steart PV, Gatter KC, Weller RO. Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins. Neuropathol Appl Neurobiol 1995;21:352-61
21. Nakagawa S, Shiraishi T, Kihara S, Tabuchi K. Detection of DNA strand breaks associated with apoptosis in human brain tumors. Virchows Arch 1995;427:175-79
22. Schiffer D, Cavalla P, Migheli A, et al. Apoptosis and cell proliferation in human neuroepithelial tumors. Neurosci Lett 1995;195: 81-84
23. Nakamura M, Konishi N, Tsunoda S, et al. Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma. Cancer 1997;80:242-49
24. Cordon-Cardo C. Mutation of cell cycle regulators: Biological and clinical implications for human neoplasia. Am J Pathol 1995;147: 545-60
25. Tomlinson IPM, Bodmer WF. Failure of programmed cell death and differentiation as causes of tumors: Some simple mathematical models. Proc Natl Acad Sci USA 1995;92:11130-34
26. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 1994;78:539-42
27. Kerr JFR, Winterford CM, Harmon BV. Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994;73:2013-26
28. Symonds H, Krall L, Remington L, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994;78: 703-11
29. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62
30. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501
31. Iseki S. DNA strand breaks in rat tissue as detected by in situ nick translation. Exp Cell Res 1986;167:311-26
32. Ansari B, Coates PJ Greenstein BD, Hall PA. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 1993;170:1-8
33. Gold R, Schmied M, Giegerich G, et al. Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest 1994;71:219-25
34. Migheli A, Cavalla P, Marino S, Schiffer D. A study of apoptosis in normal and pathologic nervous tissue after in situ end-labeling of DNA strand breaks. J Neuropathol Exp Neurol 1994;53:606-16
35. Davison FD, Groves M, Scaravilli F. The effects of formalin fixation on the detection of apoptosis in human brain by in situ end-labelling of DNA. Histochem J 1995;27:983-88
36. Hockenbery D. Defining apoptosis. Am J Pathol 1995;146:16-19
37. Kleihues P, Burger PC, Scheithauer BW. Histologic typing of tumours of the central nervous system. New York: Springer Verlag, 1993
38. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas: A simple and reproducible method. Cancer 1988;62: 2152-65
39. Gold R, Schmied M, Rothe G, et al. Detection of DNA fragmentation in apoptosis: Application of in situ nick translation to cell culture systems and tissue sections. J Histochem Cytochem 1993; 41:1023-30
40. Nelson JS, Tsukada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 1983;52:550-54
41. Fulling KH, Garcia DM. Anaplastic astrocytoma of the adult cerebrum: Prognostic value of histologic features. Cancer 1985;55: 928-31
42. Burger PC, Kleihues P. Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. Cancer 1989;63:2014-23
43. Glantz MJ, Burger PC, Herndon JE II et al. Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology 1991;41:1741-44
44. Kim DK, Hoyt J, Bacchi C, et al. Detection of proliferating cell nuclear antigen in gliomas and adjacent resection margins. Neurosurgery 1993;33:619-26
45. Dalrymple SJ, Parisi JE, Roche PC, Ziesmer SC, Scheithauer BW, Kelly PJ. Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory. Neurosurgery 1994;35:1036-45
46. Hopf NJ, Bremm J, Bohl J, Perneczky A. Image analysis of proliferating cells in tumors of the human nervous system: An immunohistological study with the monoclonal antibody Ki-67. Neurosurgery 1994;35:917-23
47. Collins JM. Deoxyribonucleic acid structure in human diploid fibroblasts stimulated to proliferate. J Biol Chem 1977;252:141-47
48. Dawson BA, Lough J. Immunocytochemical localization of transient DNA strand breaks in differentiating myotubes using in situ nick-translation. Dev Biol 1988;127:362-67
49. Olano JP, Wolf D, Keherly M, Gelman BB. Quantifying apoptosis in banked human brains using flow cytometry. J Neuropathol Exp Neurol 1996;55:1164-72
50. Gestblom C, Hoehner JC, Påhlman S. Proliferation and apoptosis in neuroblastoma: Subdividing the mitosis-karyorrhexis index. Eur J Cancer 1995;31A:458-63
51. Hoehner JC, Hedborg F, Jernberg Wiklund H, Olsen L, Påhlman S. Cellular death in neuroblastoma: In situ correlation of apoptosis and bcl-2 expression. Int J Cancer 1995;62:19-24
52. Ikeda H, Hirato J, Akami M, et al. Bcl-2 oncoprotein expression and apoptosis in neuroblastoma. J Pediatr Surg 1995;30:805-8
53. Koizumi H, Wakisaka M, Nakada K, et al. Demonstration of apoptosis in neuroblastoma and its relationship to tumour regression. Virchows Arch 1995;427:167-73
54. Troncoso JC, Sukhov RR, Kawas CH, Koliatsos VE. In situ labeling of dying cortical neurons in normal aging and in Alzheimer's disease: Correlations with senile plaques and disease progression. J Neuropathol Exp Neurol 1996;55:1134-42
55. Wester K, Bjerkvig R, Cressey L, Engebraaten O, Mørk S. Organ culture of a glioblastoma from a patient with an unusually long survival. Neurosurgery 1994;35:428-33
56. Kroemer G, Petit P, Zamzami N, Vayssière J-L, Mignotte B. The biochemistry of programmed cell death. FASEB J 1995;9:1277-87
57. Martin SJ, Green DR. Protease activation during apoptosis: Death by a thousand cuts? Cell 1995;82:349-52
58. Vaux DL, Strasser A. The molecular biology of apoptosis. Proc Natl Acad Sci USA 1996;93:2239-44
59. Salford LG, Brun A, Nirfalk S. Ten-year survival among patients with supratentorial astrocytomas grade III and IV. J Neurosurg 1988;69:506-9
60. Chandler KL, Prados MD, Malec M, Wilson CB. Long-term survival in patients with glioblastoma multiforme. Neurosurgery 1993; 32:716-20
61. Salcman M, Scholtz H, Kaplan RS, Kulik S: Long-term survival in patients with malignant astrocytoma. Neurosurgery 1994;34:219-20
62. Decaestecker C, Salmon I, Camby I, et al. Identification of high versus lower risk clinical subgroups in a group of adult patients with supratentorial anaplastic astrocytomas. J Neuropathol Exp Neurol 1995;54:371-84
63. Hsu DW, Louis DN, Efird JT, Hedley-Whyte ET. Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas. J Neuropathol Exp Neurol 1997;56:857-65
64. Laws ER Jr, Taylor WF, Clifton MB, Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 1984;61:665-73
65. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications. Cancer 1985;56:1106-11
66. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987; 59:1617-25
67. North CA, North RB, Epstein JA, Piantadosi S, Wharam MD. Low-grade cerebral astrocytomas: Survival and quality of life after radiation therapy. Cancer 1990;66:6-14
68. Kim TS, Halliday AL, Hedley-Whyte ET, Convery K. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 1991;74:27-37
69. Nicoll JAR, Candy E. Nucleolar organizer regions and post-operative survival in glioblastoma multiforme. Neuropathol Appl Neurobiol 1991;17:17-20
70. McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J. Treatment and survival of low-grade astrocytoma in adults - 1977-1988. Neurosurgery 1992;31:636-42
71. Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF. Supratentorial low-grade astrocytomas in adults. Neurosurgery 1993;32: 554-59
72. Grant R, Liang BC, Page MA, Crane DL, Greenberg HS, Junck L. Age influences chemotherapy response in astrocytomas. Neurology 1995;45:929-33
73. Jones KD, Couldwell WT, Hinton DR, et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 1994;205:1681-87
74. Macdonald DR. Neurologic complications of chemotherapy. Neurol Clin 1991;9:955-67
75. Allen A. The cardiotoxicity of chemotherapeutic drugs. Sem Oncol 1992;19:529-42
76. Balducci L, Mowry K. Pharmacology and organ toxicity of chemotherapy in older patients. Oncology (Huntingt) 1992;6(Suppl 2): 62-68
77. Gastineau DA, Hoagland HC. Hematologic effects of chemotherapy. Sem Oncol 1992;19:543-50
78. Kreisman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy. Sem Oncol 1992;19:508-20
79. Patterson WP, Reams GP Renal toxicities of chemotherapy. Sem Oncol 1992;19:521-8
80. Perry MC. Chemotherapeutic agents and hepatotoxicity. Sem Oncol 1992;19:551-65
81. Valdes Olmos RA, Hoefnagel CA, van der School JB. Nuclear medicine in the monitoring of organ function and the detection of injury related to cancer therapy. Eur J Nucl Med 1993;20:515-46
82. Gold R, Schmied M, Giegerich G, et al. The two in situ techniques do not differentiate between apoptosis and necrosis but rather reveal distinct patterns of DNA fragmentation in apoptosis [letter]. Lab Invest 1995;72:612-13
83. Arends MJ, McGregor AH, Toft NJ, Brown EJ, Wyllie AH. Susceptibility to apoptosis is differentially regulated by c-myc and mutated Ha-ras oncogenes and is associated with endonuclease availability. Br J Cancer 1993;68:1127-33
84. Wyllie AH. Apoptosis (the 1992 Frank Rose memorial lecture). Br J Cancer 1993;67:205-8
85. Alderson LM, Castleberg RL, Harsh GR IV, Louis DN, Henson JW. Human gliomas with wild-type p53 express bcl-2. Cancer Res 1995;55:999-1001
86. Bögler O, Huang H-JS, Kleihues P, Cavenee WK. The p53 gene and its role in human brain tumors. Glia 1995;15:308-27
87. Cortopassi G, Liu Y. Genotypic selection of mitochondrial and oncogenic mutations in human tissue suggests mechanisms of age-related pathophysiology. Mutat Res 1995;338:151-59
88. U HS, Espiritu OD, Kelley PY, Klauber MR, Hatton JD. The role of the epidermal growth factor receptor in human gliomas: I. The control of cell growth. J Neurosurg 1995;82:841-46
89. Weiner HL. The role of growth factor receptors in central nervous system development and neoplasia. Neurosurgery 1995;37:179-94
90. Aaronson SA. Growth factors and cancer. Science 1996;254: 1146-53
91. Ono Y, Tamiya T, Ichikawa T, et al. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 1996;55:1026-31
92. Modrich P. Mismatch repair, genetic stability, and cancer. Science 1994;266:1959-60